Key terms
About EIGR
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EIGR news
Mar 11
4:12pm ET
Christine Murray Resigns from Eiger Biopharmaceuticals Board
Mar 04
9:43am ET
Eiger BioPharmaceuticals trading resumes
Mar 04
9:38am ET
Eiger BioPharmaceuticals trading halted, volatility trading pause
Feb 20
7:15am ET
Celcuity appoints Mayer as Chief Commercial Officer
Jan 25
4:47am ET
Eiger BioPharmaceuticals CCO Eldon Mayer III Resigns
Jan 18
6:00pm ET
Eiger BioPharmaceuticals, AnGes get Zokinvy marketing approval in Japan
Jan 05
7:50pm ET
Eiger BioPharmaceuticals trading halted, news pending
Jan 04
8:04am ET
Eiger BioPharmaceuticals announces 1-for-30 reverse stock split
No recent news articles are available for EIGR
No recent press releases are available for EIGR
EIGR Financials
Key terms
Ad Feedback
EIGR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EIGR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range